Drug Database
RA

rabies vaccine (PVRV)

✓ Approved

Sanofi S.A · Vaccine · Vaccine

What is rabies vaccine?

rabies vaccine is a vaccine developed by Sanofi S.A. It is approved for therapeutic indications.

Drug Profile

Brand NamesPVRV
CompanySanofi S.A
Drug ClassVaccine, Large Molecules
StatusApproved
Sources: ClinicalTrials.gov, Sanofi S.A

Therapeutic Indications

rabies vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsRabies✓ Approved

Related Research Articles

PubMedRevue medicale suisse2026-10-22

[Nightmare or wonder : a bat on the ceiling].

Ménard Agathe A, Erard Véronique V

Rabies is an invariably fatal zoonosis in humans caused by a neurotropic virus of Lyssavirus genus. Three genotypes are endemic in Europe. Genotype 1 or RABV (Rabies lyssavirus) is the agent of classical rabies, for which dogs and certain wild carnivores serve as reservoirs; genotypes 5 and 6, respectively EBLV-1 and EBLV-2 (European bat lyssavirus type 1 and 2), have bats as reservoirs. In Switzerland, classical rabies (RABV) has been eradicated since 1999, a status shared by the majority of European Union countries. Cases of human rabies encephalitis transmitted by bats in Europe are associated with EBLV-1 and EBLV-2 but are exceptional. This article aims to present the epidemiology, pathogenesis and prevention of rabies in Switzerland.

PMID 42902968
Read full article →
PubMedRevue medicale suisse2026-10-22

[Bucket-list destinations from an infectious disease perspective].

Grounauer Louise S LS, Prongué Estelle E, Zumbrunn Samuel K SK, Calamai Pietro P et al.

Tropical countries are among the most popular destinations for Swiss travelers and pose a health challenge in terms of infectious disease risk. Arboviral diseases are one of the major infectious risks, along with rabies, hepatitis A, and malaria. Several resurgences of vaccine-preventable diseases, such as polio and yellow fever, have also been identified. In light of these data, it would appear that the safest travel destinations from an infectious disease perspective are Cuba in Latin America, Hong Kong in Asia, and the Seychelles in Africa. However, these data are subject to change and may evolve rapidly.

PMID 42902966
Read full article →
PubMedDanish medical journal2026-10-22

Early discrimination of preterm prelabour rupture of foetal membranes in nulliparous women.

Kirk Mille M, Koch Milos M MM, Nathan Nina O NO, Budtz-Jørgensen Esben E et al.

Biologic therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) have been approved in Denmark since 2022. Chest X-ray (CXR) was implemented by the Global Airways Steering Group as pre-treatment screening to identify pulmonary conditions and monitor adverse effects. This study evaluates the utility of routine CXR screening before initiating biological therapy in patients with CRSwNP. Baseline data, including chest X-ray, were collected prospectively in the nationwide Global Airways Registry (approved by the Danish Research Ethics Committee R. no.: H-21020685) and analysed in May 2025. A total of 511 patients (335 males, 176 females; mean age 46.5 ± 14.6) years were identified and included in this study; 247 patients were initiated on biologic therapy. In the treatment group, 136 (55%) had normal CXRs, and 12 (5%) had abnormal findings. Among the 264 patients who did not receive biologic treatment, 143 (54%) had normal CXRs and ten (4%) demonstrated abnormal findings. Routine baseline CXR screening before biologic therapy in patients with CRSwNP identified few abnormal findings. Accordingly, routine CXR is likely to offer limited clinical benefit. The Global Airways database is funded by GlaxoSmithKline, Sanofi and Astra Zeneca. None of the pharmaceutical companies has access to data. Not relevant.

PMID 42902751
Read full article →
PubMedFrontiers in immunology2026-10-22

A subunit vaccine protects A129 mice from death and joint swelling against lethal Chikungunya virus challenge.

Li Jiangfan J, Fang Ting T, Song Liyuan L, Qiang Li L et al.

Chikungunya virus (CHIKV) is primarily transmitted to humans through bites of infected Aedes mosquitoes, causing febrile illness as well as acute or chronic arthritis. With increasing reports in previously non-endemic regions, it poses an emerging threat to public health and a growing risk to travelers. Despite the recent approval of live-attenuated and virus-like particle-based vaccines, a safe, efficacious, and cost-effective vaccine remains urgently needed. The envelope glycoproteins E1 and E2, which play crucial roles in viral attachment and entry, are the major immunodominant structural proteins and can effectively elicit protective antibodies. We engineered mammalian cells to produce the ectodomains of the E1 and E2 glycoproteins and evaluated the protective efficacy of the resulting vaccine formulations in vivo. A two-dose vaccination regimen elicited high levels of antibodies and provided full protection against lethal challenge in A129 mice, preventing both death and joint swelling. These findings demonstrate the potential of this vaccine candidate against CHIKV and warrant its further development.

PMID 42903135
Read full article →
PubMedEpidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil2026-10-22

[Strategies to address vaccine hesitancy in Brazil: evidence synthesis].

Marques Ana Paula da Costa APDC, Gubert Vanessa Terezinha VT, Dias Adriano da Costa ADC, Gasparoto Antonio Luiz Dal Bello ALDB et al.

PMID 42903010
Read full article →
PubMedKidney research and clinical practice2026-10-22

Clinical effects of third doses of mRNA COVID-19 vaccines among hemodialysis patients: a nationwide retrospective cohort study.

Cho AJin A, Jeong Seon A SA, Seo Yu Bin YB, Park Hayne Cho HC et al.

Evidence on the effectiveness of third-dose messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccination during the Omicron-dominant period in Asian hemodialysis (HD) patients remains limited. We evaluated the clinical effectiveness of a third mRNA vaccine dose against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality in Korean HD patients. Using the Korea Disease Control and Prevention Agency-National Health Insurance Service database, we conducted a nationwide cohort study of HD patients aged ≥18 years who received two or three doses of BNT162b2 or mRNA-1273 before January 16, 2022. Study outcomes were SARS-CoV-2 infection, hospitalization, and death. Cox proportional hazards models were used to assess the associations between third-dose vaccination and clinical outcomes. Among 66,389 HD patients (mean age, 65.7 ± 12.9 years; 60.5% male), 55,125 (83.0%) received three vaccine doses and 11,264 (17.0%) received two doses. Receipt of three doses was associated with a significantly lower risk of SARS-CoV-2 infection (adjusted hazard ratio [aHR], 0.58; 95% confidence interval [CI], 0.56-0.60). Among 17,886 patients with SARS-CoV-2 infection, third-dose vaccine recipients had a lower risk of hospitalization (aHR, 0.65; 95% CI, 0.62-0.70) and 30-day mortality (aHR, 0.35; 95% CI, 0.30-0.41) compared with those who received two doses. Receipt of mRNA-1273 as the third dose was associated with lower observed risks of infection and hospitalization than receipt of BNT162b2. A third dose of an mRNA COVID-19 vaccine was associated with lower risks of SARS-CoV-2 infection, hospitalization, and mortality among HD patients during the Omicron-dominant period. These findings support the clinical importance of booster vaccination in this high-risk population.

PMID 42902884
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about rabies vaccine